Cooper Companies (NASDAQ:COO) Issues Q4 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) updated its fourth quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.050-1.090 for the period, compared to the consensus estimate of 1.200. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Cooper Companies also updated its FY 2026 guidance to 4.510-4.550 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on COO shares. Wall Street Zen upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. Stifel Nicolaus lowered their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Wells Fargo & Company reaffirmed a “sell” rating and set a $66.00 price target (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research report on Friday, June 5th. Finally, UBS Group assumed coverage on shares of Cooper Companies in a research note on Tuesday, July 28th. They set a “neutral” rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies currently has an average rating of “Hold” and an average price target of $81.64.

Cooper Companies Stock Performance

Shares of NASDAQ COO traded down $4.21 during midday trading on Wednesday, hitting $63.48. 8,383,881 shares of the company’s stock were exchanged, compared to its average volume of 2,347,124. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $12.38 billion, a PE ratio of 53.80, a price-to-earnings-growth ratio of 1.82 and a beta of 0.82. Cooper Companies has a 12 month low of $58.89 and a 12 month high of $89.83. The company’s 50 day moving average price is $72.59 and its 200 day moving average price is $70.17.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, analysts predict that Cooper Companies will post 4.63 earnings per share for the current fiscal year.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Trading of Cooper Companies

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP raised its holdings in Cooper Companies by 332.9% in the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after acquiring an additional 4,756,178 shares during the period. Generation Investment Management LLP acquired a new stake in Cooper Companies during the 4th quarter worth approximately $233,539,000. Price T Rowe Associates Inc. MD boosted its stake in Cooper Companies by 58.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after purchasing an additional 2,231,568 shares during the period. Ameriprise Financial Inc. boosted its stake in Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Cooper Companies by 247.1% in the 4th quarter. AQR Capital Management LLC now owns 1,653,678 shares of the medical device company’s stock valued at $135,535,000 after buying an additional 1,177,279 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.